Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.

Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T, Sata M.

Int J Oncol. 2012 Mar;40(3):679-85. doi: 10.3892/ijo.2011.1237. Epub 2011 Oct 20.

PMID:
22020928
2.

Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.

Guo HC, Bu HQ, Luo J, Wei WT, Liu DL, Chen H, Tong HF, Wang ZH, Wu HY, Li HH, Zuo MM, Li W, Lin SZ.

Int J Oncol. 2012 Jun;40(6):1849-57. doi: 10.3892/ijo.2012.1389. Epub 2012 Feb 29.

PMID:
22378302
3.

Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.

Nakahira S, Nakamori S, Tsujie M, Takeda S, Sugimoto K, Takahashi Y, Okami J, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M.

Anticancer Res. 2008 Jan-Feb;28(1A):179-86.

5.

Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.

Cancer Res. 2005 Oct 1;65(19):9064-72.

6.

Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.

Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, Tan W, Ni ZL, Liu HB, Lin SZ.

Int J Oncol. 2011 Nov;39(5):1123-31. doi: 10.3892/ijo.2011.1115. Epub 2011 Jul 6.

PMID:
21743963
7.

Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.

Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB.

Pancreas. 2011 Aug;40(6):966-73. doi: 10.1097/MPA.0b013e3182156d5a.

PMID:
21487323
8.
9.

Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis.

Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Saito Y.

Oncol Rep. 2011 Nov;26(5):1057-62. doi: 10.3892/or.2011.1407. Epub 2011 Jul 28.

PMID:
21805043
10.

Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.

Ahn DW, Seo JK, Lee SH, Hwang JH, Lee JK, Ryu JK, Kim YT, Yoon YB.

Pancreas. 2012 Oct;41(7):1048-57. doi: 10.1097/MPA.0b013e318249d62e.

PMID:
22513291
11.

Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.

Wang YW, Wang SJ, Zhou YN, Pan SH, Sun B.

J Cancer Res Clin Oncol. 2012 May;138(5):785-97. doi: 10.1007/s00432-012-1152-z. Epub 2012 Jan 24.

PMID:
22270965
12.

New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.

Horiuchi T, Uwagawa T, Shirai Y, Saito N, Iwase R, Haruki K, Shiba H, Ohashi T, Yanaga K.

J Surg Res. 2016 Nov;206(1):1-8. doi: 10.1016/j.jss.2016.06.047. Epub 2016 Jun 25.

PMID:
27916347
13.

Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.

Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Xue DB, Bai XW, Sun B.

Cancer Lett. 2010 Jul 1;293(1):99-108. doi: 10.1016/j.canlet.2010.01.001. Epub 2010 Feb 4.

PMID:
20137856
15.

[Regulatory effects of peroxisome proliferator-activated receptor gamma on the growth of pancreatic carcinoma].

Dong YW, Wang XP, Wu K, Wu LY, Zhang RL.

Zhonghua Nei Ke Za Zhi. 2003 Jul;42(7):479-82. Chinese.

PMID:
12921608
16.

The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.

Wang Y, Kuramitsu Y, Kitagawa T, Tokuda K, Baron B, Akada J, Nakamura K.

Target Oncol. 2015 Dec;10(4):575-81. doi: 10.1007/s11523-015-0370-0.

PMID:
25940934
17.

Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.

Liu DL, Bu H, Li H, Chen H, Guo HC, Wang ZH, Tong HF, Ni ZL, Liu HB, Lin SZ.

Int J Oncol. 2012 Apr;40(4):1049-57. doi: 10.3892/ijo.2011.1285. Epub 2011 Dec 7.

18.

[An experimental study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA].

Kong R, Sun B, Wang SJ, Pan SH, Wang G, Chen H, Xue DB, Jiang HC.

Zhonghua Wai Ke Za Zhi. 2010 Jan 15;48(2):128-33. Chinese.

PMID:
20302733
19.

[Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].

Wang SJ, Sun B, Pan SH, Chen H, Kong R, Li J, Xue DB, Bai XW, Jiang HC.

Zhonghua Wai Ke Za Zhi. 2010 Apr 1;48(7):530-4. Chinese.

PMID:
20646665
20.

Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.

Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M.

Cell Death Dis. 2011 Apr 28;2:e152. doi: 10.1038/cddis.2011.36.

Supplemental Content

Support Center